LIN28B is an RNA-binding protein involved in regulating developmental timing, stem cell pluripotency, and metabolism. It functions by binding to RNA molecules, including precursors of let-7 microRNAs, to inhibit their maturation and influence cellular differentiation and oncogenic processes. Antibodies targeting LIN28B are essential tools for studying its expression, localization, and functional roles in both physiological and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to detect LIN28B protein levels in tissues or cultured cells. Research has highlighted LIN28B’s overexpression in cancers (e.g., hepatocellular carcinoma, neuroblastoma) and its association with poor prognosis, making it a biomarker of interest. Unlike its paralog LIN28A, LIN28B is often linked to embryonic development and germ cell tumors. Validating LIN28B antibodies requires specificity checks, as cross-reactivity with LIN28A or isoforms may occur. Studies using these antibodies have advanced understanding of LIN28B’s role in reprogramming somatic cells, regulating metabolism, and promoting tumorigenesis. Its dual function in promoting pluripotency and oncogenesis underscores its therapeutic potential, driving demand for reliable antibodies in both basic research and translational applications.